Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-04

Study Completion Date

2022-01-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical study was designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and combination treatments in adult patients with non-alcoholic fatty liver disease (NAFLD) who manifest a non-alcoholic steatohepatitis (NASH)-like biomarker phenotype.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

NCT02855164

Non-alcoholic Steatohepatitis (NASH)

TERMINATED PHASE2

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

NCT04065841

Non Alcoholic Steatohepatitis (NASH)

TERMINATED PHASE2

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

NCT03517540

Non-alcoholic Steatohepatitis (NASH)

COMPLETED PHASE2

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

NCT03205150

Obese Patients With Non-alcoholic Steatohepatitis (NASH)

COMPLETED PHASE2

Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease

NCT05084404

Nonalcoholic Fatty Liver Nonalcoholic Steatohepatitis

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a Phase II, non-confirmatory, multicenter, open label, platform study in NAFLD participants with a NASH-like biomarker phenotype to examine the effects of single and combination therapies over 12 weeks of treatment. The study consisted of four distinct study periods:

* Screening Period (Day -60 to -28): Lasted up to a maximum of 33 days where participants were assessed for inclusion and exclusion criteria prior the baseline assessments.
* Baseline Period (Day -27 to -1): Lasted up to a maximum of 27 days and comprised baseline assessments and randomization.
* Treatment Period (Day 1 to 85): Participants were randomized in a 1:1 ratio to LYS006 20 mg (twice a day) arm or to LYS006 20 mg (twice a day) and tropifexor 200ug (once a day). Participants were treated daily during 12 weeks.
* Follow-up Period (Day 85 to 113): After completion of the treatment period, participants were observed until the End Of Study (EOS) visit at Day 113.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-alcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LYS006

LYS006 20 mg was administered orally twice per day (b.i.d) for 12 weeks

Group Type EXPERIMENTAL

LYS006

Intervention Type DRUG

5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks

LYS006 + LJN452

LYS006 20 mg was administered orally twice per day (b.i.d) in addition to LJN452 200ug administered orally once daily for 12 weeks

Group Type EXPERIMENTAL

Tropifexor

Intervention Type DRUG

100 ug LJN452 capsules orally administered 200ug once daily for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LYS006

5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks

Intervention Type DRUG

Tropifexor

100 ug LJN452 capsules orally administered 200ug once daily for 12 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LJN452

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Phenotypic diagnosis of NASH based on the presence of all of the following:

* ALT ≥ 43 IU/L (males) or ≥ 28 IU/L (females)
* BMI ≥ 27 kg/m2 (race other than Asian) or ≥ 23 kg/m2 (Asian race)
* History of type 2 diabetes mellitus with HbA1c ≤ 9%
* ELF test score ≥ 8.5 and ≤ 10.5
* Liver fat ≥ 8%
* Patients must weigh between 40 kg (88 lbs.) and 150 kg (330 lbs.)

Exclusion Criteria

* Use of other investigational drugs within 5 half-lives of randomization or within 3 months, whichever is longer
* Use of obeticholic acid (OCA) or pharmacologically-active weight loss drugs within 1 month of randomization
* Use of strong CYP3A4/5 inhibitors or strong CYP3A4 inducers within 5 half-lives or 7 days of randomization, whichever is longer
* History or presence of other concomitant liver diseases
* History or current diagnosis of ECG abnormalities
* Patients with contraindications to MRI imaging
* Current or history of significant alcohol consumption
* Clinical evidence of hepatic decompensation or severe liver impairment
* Women of child bearing potential (unless on highly effective methods of contraception)
* Presence of liver cirrhosis
* Use of OAT3 inhibitors within 5 half-lives or 7 days of randomization, whichever is longer

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No